E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Polymyalgia rheumatica is a condition that causes pain, stiffness and inflammation in the muscles around the shoulders, neck and hips. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036099 |
E.1.2 | Term | Polymyalgia rheumatica |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To identify whether a prednisolone dose adjustment is necessary to provide equivalent efficacy when administered with SPI-62 in subjects with PMR and, if so, estimate the adjustment
|
|
E.2.2 | Secondary objectives of the trial |
• To observe whether SPI-62 mitigates prednisolone toxicity in subjects with PMR and, if so, estimate the appropriate dose to administer in combination withprednisolone • To characterize the pharmacological activity of SPI-62 in subjects with PMR • To report the safety of SPI-62 in subjects with PMR treated with prednisolone |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Able to understand the nature and scope of the trial. 2. Written informed consent given prior to any trial-related procedures. 3. At least 18 years old. 4. Diagnosis of polymyalgia rheumatica according to EULAR/ACR classification criteria. 5. Absence of PMR relapse based on symptoms. 6. Absence of PMR relapse based on acute phase markers 7. Daily oral prednisolone 10 mg dose that will have been stable for at least 1 week at the Baseline Visit and is expected to remain stable during the treatment period. |
|
E.4 | Principal exclusion criteria |
1. Known hypersensitivity to prednisolone, SPI-62 or any of the excipients. 2. Systemic fungal infection. 3. Administration of any vaccine within 4 weeks prior to the Baseline Visit or during the trial. 4. Any relative contraindication for prednisolone of sufficient severity that the investigator considers that the subject should receive immediate additional treatment or not continue prednisolone. 5. Fulfills all criteria and clearly qualifies to use methotrexate according to national or EULAR/ACR guideline for treatment of PMR, unless the subject refuses to take methotrexate or has a contraindication to methotrexate. 6. A diagnosis or any clinical features of giant cell arteritis. 7. Any known autoimmune disease (e.g., late-onset rheumatoid arthritis) other than PMR. 8. Use of medications other than oral prednisolone for treatment of PMR. 9. Use of other medications likely to interfere with trial assessments. See Section 7 for lists of medications that are and are not allowed during the trial. Use of any other medication (prescription, OTC, or traditional) or supplement within 4 weeks of the Baseline Visit is allowed only if the medication and dose (or PRN use) are approved by the Medical Monitor or Sponsor, the dose has been stable for at least 4 weeks, and the dose is expected to remain stable for the duration of the trial. 10. History of clinically significant labile diabetes or hypertension during glucocorticoid therapy. 11. History or diagnosis of endogenous hypercortisolism. 12. Moderate or severe renal impairment. Defined by an estimated glomerular filtration rate (2021 CKD-EPI creatinine equation) repeatedly < 60 mL/min/1.73m2. 13. Medically significant liver disease. Including cirrhosis, chronic active hepatitis, chronic persistent hepatitis, or subjects with serum total bilirubin > 1.5 × ULN (unless previously diagnosed with benign Gilbert’s disease) or serum ALT or AST >3 × ULN. 14. Medically significant cardiovascular or ECG abnormalities. This includes subjects with recent (< 1 year) myocardial infarction or stroke, orthostatic or vasovagal syncope, QT interval corrected (QTc) interval > 500 ms, uncorrected QT interval > 600 ms, or evidence of significant, life-threatening arrhythmia or bradycardia (heart rate < 45 bpm). 15. History of idiopathic thrombocytopenic purpura. 16. Recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which is defined as: Positive lab-based test (polymerase chain reaction or antigen test) for active infection within the past 4 weeks or hospitalization for coronavirus disease 2019 (COVID-19) within the past 6 months. 17. History of cancer within 3 years other than non-melanoma skin cancer or early-stage prostate cancer (not dependent on hormone-suppression therapy). 18. Any major surgery, or significant post-operative sequelae, within 1 month prior to informed consent or planned during the trial. 19. Pregnant, lactating, or woman of child-bearing potential unwilling to adhere to highly effective contraceptive use or abstinence as defined in Appendix 5. 20. Man unwilling to adhere to highly effective contraceptive use or abstinence as defined in Appendix 5. 21. Participation in any clinical trial of an experimental drug within 5 half-lives or 1 month prior to informed consent (or 3 months for biologic and long-lasting experimental therapies), whichever is longer. 22. Receipt of blood products within 2 months prior to Screening. 23. Donation of blood from 3 months prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening. Participants are not to donate blood, plasma, or platelets during the trial. 24. Any current or prior medical condition expected to interfere with the conduct of the trial or the evaluation of its results (e.g., asthma that requires regular or intermittent glucocorticoid treatment), or that requires immediate medical attention (e.g., uncontrolled diabetes or hypertension). 25. Employees of the Sponsor or employees or relatives of the Investigator. 26. Persons committed to an institution by virtue of a judicial order or an order issued by an administrative authority. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Fibrinogen, erythrocyte sedimentation ratio, C-reactive protein |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
oral glucose tolerance test glucose area under the concentration‑time curve, osteocalcin, urinary 11β-hydroxysteroid dehydrogenase type 1 ratio |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
6 sequential cohorts |
sequential group |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 9 |